0.4472
price up icon11.60%   0.0465
after-market Dopo l'orario di chiusura: .48 0.0328 +7.33%
loading
Precedente Chiudi:
$0.4007
Aprire:
$0.4382
Volume 24 ore:
5.15M
Relative Volume:
2.91
Capitalizzazione di mercato:
$72.59M
Reddito:
$9.10M
Utile/perdita netta:
$-82.47M
Rapporto P/E:
-0.771
EPS:
-0.58
Flusso di cassa netto:
$-72.32M
1 W Prestazione:
+40.58%
1M Prestazione:
+6.17%
6M Prestazione:
-46.45%
1 anno Prestazione:
-36.99%
Intervallo 1D:
Value
$0.43
$0.4777
Intervallo di 1 settimana:
Value
$0.3251
$0.4777
Portata 52W:
Value
$0.285
$1.07

Vaxart Inc Stock (VXRT) Company Profile

Name
Nome
Vaxart Inc
Name
Telefono
(650) 550-3500
Name
Indirizzo
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Dipendente
105
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-14
Name
Ultimi documenti SEC
Name
VXRT's Discussions on Twitter

Confronta VXRT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VXRT
Vaxart Inc
0.4472 72.59M 9.10M -82.47M -72.32M -0.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Vaxart Inc Stock (VXRT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-15 Iniziato Oppenheimer Outperform
2021-12-29 Ripresa Jefferies Buy
2021-11-02 Iniziato Cantor Fitzgerald Overweight
2021-06-29 Downgrade B. Riley Securities Buy → Neutral
2021-06-24 Iniziato Jefferies Buy
2021-06-11 Iniziato Piper Sandler Overweight
2020-08-12 Reiterato H.C. Wainwright Buy
2020-07-13 Iniziato B. Riley FBR Buy
Mostra tutto

Vaxart Inc Borsa (VXRT) Ultime notizie

pulisher
02:43 AM

Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News

02:43 AM
pulisher
01:11 AM

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

01:11 AM
pulisher
11:20 AM

Federal government lifts hold on Peninsula biotech company's vaccine trial - The Business Journals

11:20 AM
pulisher
09:03 AM

Vaxart resumes BARDA-funded trial activities - Investing.com

09:03 AM
pulisher
Apr 22, 2025

Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News

Apr 22, 2025
pulisher
Apr 19, 2025

Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com

Apr 19, 2025
pulisher
Apr 16, 2025

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan

Apr 16, 2025
pulisher
Apr 16, 2025

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - The Globe and Mail

Apr 16, 2025
pulisher
Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Proprietary - Vaxart Inc.

Apr 11, 2025
pulisher
Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Mar 30, 2025

RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville

Mar 30, 2025
pulisher
Mar 28, 2025

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 28, 2025
pulisher
Mar 27, 2025

Vaxart reports inducement grants under Nasdaq listing rule - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener

Mar 27, 2025
pulisher
Mar 24, 2025

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 24, 2025
pulisher
Mar 22, 2025

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 22, 2025
pulisher
Mar 21, 2025

Oral - Vaxart Inc.

Mar 21, 2025
pulisher
Mar 21, 2025

Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire

Mar 21, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Inc. (VXRT) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

FDA Mid-Month ID Food Recall Safety Updates - ContagionLive

Mar 19, 2025
pulisher
Mar 14, 2025

Pipeline - Vaxart Inc.

Mar 14, 2025
pulisher
Mar 13, 2025

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq

Mar 13, 2025

Vaxart Inc Azioni (VXRT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Capitalizzazione:     |  Volume (24 ore):